Exelixis Q4 2023 revenue $479.7M, GAAP EPS $0.27, non-GAAP $0.33; FY revenue $1.83B

EXELIXIS, INC.

2023-FY EPS reported $0.65 revenue$1,830,208,000

Total Q4 revenues $479.7M (up from $423.9M YoY); cabozantinib net product revenues $429.3M.
GAAP diluted EPS $0.27 (Q4) and $0.65 (FY); non-GAAP diluted EPS $0.33 (Q4) and $0.90 (FY).
FY 2023 total revenues $1.83B, up 14% from $1.61B; net product revenues $1.63B.
R&D expenses $244.7M (Q4) vs $336.8M YoY; SG&A $131.4M vs $119.3M YoY.
Pipeline: regulatory strategies for cabozantinib label expansions; MSN IP litigation ruling expected spring 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EXELIXIS, INC. reported financial results for quarter and year ended December 31, 2023.

Period: quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 6, 2024, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter and full year ended December 29, 2023, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

EXELIXIS, INC. filing history →

Source: SEC EDGAR

accession 0000939767-24-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.